Bo H. Chao

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 636 citations · Full text

Non-small-cell Lung Cancer, Medicine, Pathology +7

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

David R. Spigel, Jamie E. Chaft, Scott Gettinger et al. · Journal of Thoracic Oncology · 2018 · 169 citations · Full text

Biomarker (Medicine), Therapeutic Drug Monitoring, Biomarker Analysis +7

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).

David R. Spigel, Jamie E. Chaft, Scott Gettinger et al. · Journal of Clinical Oncology · 2015 · 73 citations

Pd-l1–selected Patients, Immunology, Cohort 1 +17

Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737

Paula M. Hauck, Bo H. Chao, Julie Litz et al. · Molecular Cancer Therapeutics · 2009 · 70 citations

Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with <scp>K</scp>RAS‐activated tumors

Miguel A. Villalona‐Calero, Elaine T. Lam, Gregory A. Otterson et al. · Cancer · 2015 · 67 citations · Full text